0001628280-25-037430
SEC filingRevenue declined 6% YoY as membership fell; medical costs outpaced revenue leading to negative gross profit and wider net loss.
In the second quarter of 2025, Agilon Health reported total revenue of $1.395 billion, a 6% decrease from $1.483 billion in the same period of 2024. The decline was primarily driven by a 3% reduction in Medicare Advantage membership to 497,500, attributable to partnership exits during 2024, along with lower risk adjustment revenue including unfavorable prior period development, and higher costs associated with Medicare Part D prescription drug benefits which reduce revenue. Gross profit swung from positive $32.2 million to a loss of $52.4 million, as medical services expense increased 5% to $1.445 billion, outpacing revenue. Medical margin, a non-GAAP measure that subtracts medical services expense from medical services revenue, turned negative $53.2 million compared to positive $105.5 million a year ago, reflecting an average medical expense per member increase of 7% while membership declined. Net loss widened to $104.4 million from $30.7 million, and Adjusted EBITDA loss expanded to $83.3 million from $2.8 million, driven by the gross margin compression and higher operating costs despite reductions in general and administrative expenses.
The company operates as a single segment. Other medical expenses, which include partner physician incentive compensation and other provider costs, decreased 97% to $2.2 million, largely due to a $65.2 million reduction in partner physician incentive expense which turned negative ($34.9 million) as losses were generated in certain geographies. This shift reflects the impact of partnership exits and unfavorable medical cost experience. Platform support costs (general and administrative) decreased 10% to $37.4 million, and investments to support geography entry declined to $4.2 million, indicating a pullback in expansion spending.
Management did not provide specific quantitative guidance for future periods. The MD&A notes the expectation of continued operating losses and negative cash flows from operations due to investments in expanding the business. The company highlighted the payor data pipeline implemented in Q1 2025 to improve risk adjustment visibility, which may benefit future revenue. No explicit outlook on membership or margin recovery was given, but the trend of partnership exits and higher medical costs suggests near-term challenges. The company believes existing cash and marketable securities ($327 million combined) and credit facility borrowing capacity will be sufficient for at least the next 12 months.
Cash and cash equivalents stood at $171.4M as of June 30, 2025, down from $188.2M at year-end 2024. Marketable securities (all available-for-sale, investment-grade) totaled $155.6M. The company had $35.0M drawn on its secured term loan facility and $80.6M in outstanding letters of credit, leaving $19.4M available under the $100M revolver. Total debt was $34.9M (all current). Shareholders' equity was $408.9M, including a $1.68B accumulated deficit. The consolidated VIEs reported $1.19B in assets and $1.20B in liabilities, with no recourse to the primary beneficiary. Medical claims payable (including IBNR estimates) were $1.04B.
No purchase commitments (e.g., supply agreements or capacity reservations) are disclosed in the Notes. The company accrues $35.0M for long-term contingencies (unasserted claims). Operating lease liabilities total $6.4M long-term. The credit facility matures February 2026. No off-balance-sheet commitments beyond surety bonds ($131.6M) related to unconsolidated CMS ACO entities.
No share repurchases or dividends occurred. No new buyback authorization was announced. Debt repayment was $0. Capital expenditures were $7.1M in the first half, representing 0.24% of total revenues. No debt was issued. The company raised $2.6M from stock option exercises and paid $2.9M for net share settlements of vested RSUs.
The company operates as a single operating and reportable segment. No geographic or payor-level segment data is provided. Revenue concentration: two payors each accounted for 14% of Q2 2025 total revenue (Payor A, Payor B); three other payors each exceeded 10%. No segment-level operating income is disclosed.
For the six months ended June 30, 2025, the company reported a net loss of ($92,258) thousand, while net cash used in operating activities was ($67,072) thousand. The difference is primarily attributable to non-cash items: stock-based compensation ($32,101 thousand), depreciation and amortization ($14,195 thousand), and loss from equity method investments ($18,084 thousand), partially offset by a positive change in working capital of $14,081 thousand (versus a $67,312 thousand use in the prior period). This indicates that despite the net loss, the cash burn from operations is narrower than the loss due to non-cash charges.
Capital expenditures (purchase of property and equipment) were $7,099 thousand, representing a modest capex intensity relative to the operational cash outflows. Free cash flow (CFO minus capex) would be approximately ($74,171) thousand, highlighting that operating activities do not yet internally fund capital investments or shareholder returns. No share repurchases or dividends were paid during the period.
Anomalies/Working Capital: The swing in operating assets and liabilities from a large negative ($67,312 thousand) to a positive $14,081 thousand suggests a significant reversal in working capital timing, which should be monitored for sustainability.